共 50 条
- [31] Addition of Local Therapy to EGFR TKI Showed Survival Benefit in EGFR-Mutant NSCLC pts with Oligometastatic or Oligoprogressive Liver MetastasesJOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S336 - S336Jiang, T.Zhou, C.Wang, H.Chu, Q.
- [32] Predictive impact of different exon 19 deletions in EGFR-mutant NSCLC treated with first-line TKIsJOURNAL OF CLINICAL ONCOLOGY, 2017, 35Rossi, SabrinaToschi, LucaFinocchiaro, GiovannaD'Argento, EttoreDi Noia, Vincenzo PioCassano, AlessandraBonomi, MariaCerchiaro, EleonoraCeresoli, Giovanni LucaBeretta, Giordano D.Barone, CarloSantoro, Armando
- [33] Adding chemotherapy to TKI: can we improve first-line treatment for EGFR-mutated NSCLC patients?TRANSLATIONAL CANCER RESEARCH, 2016, 5 : S1413 - S1416Passiglia, FrancescoRusso, Antonio
- [34] Assessment of early resistance mechanisms to first-line osimertinib in EGFR-mutant NSCLC using spatial transcriptomicsANNALS OF ONCOLOGY, 2022, 33 (07) : S1015 - S1016de Garibay, G. RuizRoch, B.Garrido Lopez, P.Isla, D.Aguado, C.Callejo Perez, A.Marse Fabregat, R.Garcia Campelo, M. R.Blasco Cordellat, A.Sanchez Torres, J. M.Bernabe Caro, R.Juan Vidal, O. J.Carpeno, J. De CastroFranco, F. F.Ramos Garcia, I.Gomez Rueda, A.Conde Gallego, E.Ponce Aix, S.Paz-Ares, L.Zugazagoitia, J.
- [35] Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: a multicenter observational studyBMC Cancer, 19Gwo-Fuang HoChee-Shee ChaiAdlinda AlipMohd Ibrahim A. WahidMatin Mellor AbdullahYoke-Ching FooSoon-Hin HowAdel ZaatarKai-Seng LamKin-Wah LeongJohn-Seng-Hooi LowMastura Md YusofErica Chai-Yong LeeYok-Yong TohChong-Kin Liam
- [36] Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: a multicenter observational studyBMC CANCER, 2019, 19 (01)Ho, Gwo-FuangChai, Chee-SheeAlip, AdlindaWahid, Mohd Ibrahim A.Abdullah, Matin MellorFoo, Yoke-ChingHow, Soon-HinZaatar, AdelLam, Kai-SengLeong, Kin-WahLow, John-Seng-HooiYusof, Mastura MdLee, Erica Chai-YongToh, Yok-YongLiam, Chong-Kin
- [37] Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective studyJOURNAL OF TRANSLATIONAL MEDICINE, 2019, 17 (1)Wang, WenxianWang, HongLu, PeihuaYu, ZongyangXu, ChunweiZhuang, WuSong, Zhengbo
- [38] Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective studyJournal of Translational Medicine, 17Wenxian WangHong WangPeihua LuZongyang YuChunwei XuWu ZhuangZhengbo Song
- [39] Liver Metastases Is the Negative Predictive Factor for First-Line EGFR TKIs Therapy in NSCLC Patients with EGFR MutationJOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1246 - S1247Jiang, TaoZhou, Caicun
- [40] Comparison of EGFR-TKI and chemotherapy in the first-line treatment of advanced EGFR mutation-positive NSCLCNEOPLASMA, 2013, 60 (04) : 425 - 431Fiala, O.Pesek, M.Finek, J.Benesova, L.Bortlicek, Z.Minarik, M.